The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Importance of Disulfide Bond re-arrangement in vitro and in vivo: Evidence and Approaches to Address It Franta Hubálek, Novo Nordisk A/S
Development of a Rapid and Automated, Compliance Ready Workflow for Full Sequence Coverage of RNAi Therapeutics Jennifer Nguyen, Alnylam Pharmaceuticals
Elucidation, Characterization and Monitoring of a Unique Tyrosine Sulfation Post-Translational Modification During Bispecific Antibody Process Development and Scaleup David Mahon, Bristol-Myers Squibb Company